KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Income from Continuing Operations (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Income from Continuing Operations data on record, last reported at 31860000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 86.81% year-over-year to 31860000.0; the TTM value through Dec 2025 reached 83784000.0, down 89.83%, while the annual FY2025 figure was 83784000.0, 89.83% down from the prior year.
  • Income from Continuing Operations reached 31860000.0 in Q4 2025 per AQST's latest filing, down from 15446000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 8068000.0 in Q1 2023 and bottomed at 31860000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 13037000.0, with a median of 13024000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: surged 161.03% in 2023, then crashed 465.55% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 28945000.0 in 2021, then skyrocketed by 57.33% to 12352000.0 in 2022, then skyrocketed by 34.33% to 8111000.0 in 2023, then crashed by 110.27% to 17055000.0 in 2024, then crashed by 86.81% to 31860000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 31860000.0 in Q4 2025, 15446000.0 in Q3 2025, and 13548000.0 in Q2 2025.